Hindson Benjamin J.'s Form 4 filing
10x Genomics, Inc. (TXG) · filed Sep 3, 2021
- Accession no.
- 0001209191-21-054899
- Filed
- Sep 3, 2021
- Trade date
- Sep 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.40M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hindson Benjamin J.CIK 0001786391 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 | Class A Common Stock | MOption exerciseAcquired | +41,666 | $5.04 | +$209,996.64 | 88,783 | Direct | |
| Sep 1, 2021 | Class A Common Stock | SSaleDisposed | −1,049 | $174.39F2 | −$182,935.11 | 87,734 | Direct | |
| Sep 1, 2021 | Class A Common Stock | SSaleDisposed | −2,728 | $175.69F3 | −$479,282.32 | 85,006 | Direct | |
| Sep 1, 2021 | Class A Common Stock | SSaleDisposed | −7,530 | $176.65F4 | −$1,330,174.5 | 77,476 | Direct | |
| Sep 1, 2021 | Class A Common Stock | SSaleDisposed | −21,145 | $177.72F5 | −$3,757,889.4 | 56,331 | Direct | |
| Sep 1, 2021 | Class A Common Stock | SSaleDisposed | −8,586 | $178.56F6 | −$1,533,116.16 | 47,745 | Direct | |
| Sep 1, 2021 | Class A Common Stock | SSaleDisposed | −628 | $179.20F7 | −$112,537.6 | 47,117 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2021 | Class A Common Stock | MOption exerciseDisposed | −41,666 | $0.00 | $0 | 102,782 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $174.14 to $175.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $175.14 to $176.135. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $176.14 to $177.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $177.14 to $178.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $178.14 to $179.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $179.14 to $179.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Scientific Officer and President